258 related articles for article (PubMed ID: 24055775)
21. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
22. Serum tartrate-resistant acid phosphatase isoforms in rheumatoid arthritis.
Janckila AJ; Neustadt DH; Nakasato YR; Halleen JM; Hentunen T; Yam LT
Clin Chim Acta; 2002 Jun; 320(1-2):49-58. PubMed ID: 11983200
[TBL] [Abstract][Full Text] [Related]
23. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
24. Alternative immunoassay for tartrate-resistant acid phosphatase isoform 5b using the fluorogenic substrate naphthol ASBI-phosphate and heparin.
Janckila AJ; Simons RM; Yam LT
Clin Chim Acta; 2004 Sep; 347(1-2):157-67. PubMed ID: 15313154
[TBL] [Abstract][Full Text] [Related]
25. Significance of serum TRACP in rheumatoid arthritis.
Janckila AJ; Neustadt DH; Yam LT
J Bone Miner Res; 2008 Aug; 23(8):1287-95. PubMed ID: 18410226
[TBL] [Abstract][Full Text] [Related]
26. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients.
Chao TY; Yu JC; Ku CH; Chen MM; Lee SH; Janckila AJ; Yam LT
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):544-50. PubMed ID: 15701839
[TBL] [Abstract][Full Text] [Related]
27. Utility of serum tartrate-resistant acid phosphatase isoform 5b, bone alkaline phosphatase and osteocalcin in osteoporotic fractures in Chinese patients.
Cao Y; Liu X; Xu H
Clin Lab; 2012; 58(7-8):845-50. PubMed ID: 22997989
[TBL] [Abstract][Full Text] [Related]
28. New and traditional serum markers of bone metabolism in the detection of skeletal metastases.
Plebani M; Bernardi D; Zaninotto M; De Paoli M; Secchiero S; Sciacovelli L
Clin Biochem; 1996 Feb; 29(1):67-72. PubMed ID: 8929827
[TBL] [Abstract][Full Text] [Related]
29. Clinical usefulness of serum carboxyterminal propeptide of type I procollagen and pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer.
Akimoto S; Akakura K; Shimazaki J
Jpn J Clin Oncol; 1996 Jun; 26(3):157-63. PubMed ID: 8656556
[TBL] [Abstract][Full Text] [Related]
30. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
31. [Development for the determination of band 5b tartrate-resistant acid phosphatase activity in serum].
Uchida K; Nakanishi M; Yoh K
Rinsho Byori; 2001 Jan; 49(1):51-5. PubMed ID: 11215484
[TBL] [Abstract][Full Text] [Related]
32. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis.
Chu P; Chao TY; Lin YF; Janckila AJ; Yam LT
Am J Kidney Dis; 2003 May; 41(5):1052-9. PubMed ID: 12722040
[TBL] [Abstract][Full Text] [Related]
33. Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer.
Kong QQ; Sun TW; Dou QY; Li F; Tang Q; Pei FX; Tu CQ; Chen ZQ
Int J Biol Markers; 2007; 22(3):214-20. PubMed ID: 17922466
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of tartrate-resistant acid phosphatase (TRACP) 5b as bone resorption marker in irradiated bone metastases.
Mose S; Menzel C; Kurth AA; Obert K; Ramm U; Eberlein K; Boettcher HD; Pichlmeier U
Anticancer Res; 2005; 25(6C):4639-45. PubMed ID: 16334155
[TBL] [Abstract][Full Text] [Related]
35. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK
Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
[TBL] [Abstract][Full Text] [Related]
36. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
[TBL] [Abstract][Full Text] [Related]
37. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
Wakabayashi H; Nakajima K; Mizokami A; Namiki M; Inaki A; Taki J; Kinuya S
Ann Nucl Med; 2013 Nov; 27(9):802-7. PubMed ID: 23828554
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer.
Horiguchi T; Tachikawa S; Kondo R; Hirose M; Teruya S; Ishibashi A; Banno K
Jpn J Clin Oncol; 2000 Apr; 30(4):174-9. PubMed ID: 10830985
[TBL] [Abstract][Full Text] [Related]
39. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
[TBL] [Abstract][Full Text] [Related]
40. Pyridinoline cross-linked carboxyterminal telopeptide of type I collagen as a useful marker for monitoring metastatic bone activity in men with prostate cancer.
Noguchi M; Noda S
J Urol; 2001 Sep; 166(3):1106-10. PubMed ID: 11490307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
